Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors thank members of the National Centre for Infections in Cancer Clinical trials team (Department of Infectious Diseases), Ms Rebecca Blackwood and Ms Trish Joyce (Department of Hematology) and Ms Gail Rowan (Department of Pharmacy) for their help in the conduct of this study.

Author contributions

Study Design: V.G.H, B.W.T, M.S., M.Y., K.K, O.N., J.F.S, V.W. Data Analysis: V.G.H, B.W.T. Data collection: V.G.H, C.L. Manuscript Writing: All authors.

Disclosure statement

BWT has been on the advisory board for Moderna, Takeda, and CSL-Behring and received research funding from MSD, Sanofi, and Seqirus. MAS has been on data safety monitoring and adjudication committees for Cidara, Roche, and Pfizer. She has received research funding from Gilead Sciences, Merck, F2G and sat on advisory boards for Gilead Sciences, F2G, Cidara, Takeda, and Merck. JFS has been on the advisory board for AbbVie, Astra Zeneca, Beigene, BMS, Gilead, Roche, Janssen, and scientific advisory board for Genor Bio. He has received research funding from AbbVie, BMS, and Roche. He has been part of the speakers’ bureau for AbbVie, BMS, and Roche. He is a consultant and has given expert testimony to TG Therapeutics. All other authors have no conflicts of interest to disclose.

Data availability statement

De-identified data that support the findings of this study are available for ethics approved studies from the corresponding author upon reasonable request. Data transfer agreement will be required.

Additional information

Funding

V.G.H is supported by a National Health and Medical Research Council post-graduate PhD scholarship [#2014210]. BWT is supported by the Australian Government Medical Research Future Fund Investigator Fellowship [EL-2, #1195894]. This work was supported by the NHMRC Leadership Investigator Grant to KK [#1173871], NHMRC Emerging Leadership Level 1 Investigator Grant to THON [#1194036], and MRFF Award [#2016062] to KK, THON, and BT.